相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Novel Mechanisms for the Antifibrotic Action of Nintedanib
Sunad Rangarajan et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2016)
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
Andreas du Bois et al.
LANCET ONCOLOGY (2016)
Enhanced cellular uptake of nanoparticles by increasing the hydrophobicity of poly(lactic acid) through copolymerization with cell-membrane-lipid components
Mariam Samadi Moghaddam et al.
CHEMICAL COMMUNICATIONS (2015)
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
David Bender et al.
GYNECOLOGIC ONCOLOGY (2015)
Formulation and Optimization of Nonionic Surfactants Emulsified Nimesulide-Loaded PLGA-Based Nanoparticles by Design of Experiments
Ceyda Tuba Sengel Turk et al.
AAPS PHARMSCITECH (2014)
Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance
Huijun Zhu et al.
BIOMATERIALS (2014)
A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study
Don S. Dizon et al.
GYNECOLOGIC ONCOLOGY (2014)
Vitamin E-based nanomedicines for anti-cancer drug delivery
Nicolas Duhem et al.
JOURNAL OF CONTROLLED RELEASE (2014)
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Martin Reck et al.
LANCET ONCOLOGY (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo Kian Hoe et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Applying Synthetic Lethality for the Selective Targeting of Cancer
Donal P. McLornan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53
Xiangbing Meng et al.
GYNECOLOGIC ONCOLOGY (2013)
The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
Pavla Brachova et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Controlled preparation and antitumor efficacy of vitamin E TPGS-functionalized PLGA nanoparticles for delivery of paclitaxel
Guoying Wang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2013)
Integrated genomic characterization of endometrial carcinoma
Gad Getz et al.
NATURE (2013)
Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53
Xiangbing Meng et al.
OBSTETRICS AND GYNECOLOGY INTERNATIONAL (2013)
Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks
Michael J. Lee et al.
CELL (2012)
PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect
Sarbari Acharya et al.
ADVANCED DRUG DELIVERY REVIEWS (2011)
Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents
R. Dinarvand et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2011)
Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study
Carol Aghajanian et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Effect of serum proteins on polystyrene nanoparticle uptake and intracellular trafficking in endothelial cells
Daniela Guarnieri et al.
JOURNAL OF NANOPARTICLE RESEARCH (2011)
Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance
Qing-feng Xiang et al.
CELLULAR ONCOLOGY (2011)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Delivering nanomedicine to solid tumors
Rakesh K. Jain et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Management of women with uterine papillary serous cancer: A Society of Gynecologic Oncology (SGO) review
David M. Boruta et al.
GYNECOLOGIC ONCOLOGY (2009)
The DNA-damage response in human biology and disease
Stephen P. Jackson et al.
NATURE (2009)
BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy
Frank Hilberg et al.
CANCER RESEARCH (2008)
Novel molecular profiles of endometrial cancer - new light through old windows
A. Doll et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2008)
CDC25 phosphatases in cancer cells: key players? Good targets?
Rose Boutros et al.
NATURE REVIEWS CANCER (2007)
Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells
Lina Albitar et al.
GYNECOLOGIC ONCOLOGY (2007)
p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage
H. Christian Reinhardt et al.
CANCER CELL (2007)
Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers
CA Hamilton et al.
BRITISH JOURNAL OF CANCER (2006)
Targeting multidrug resistance in cancer
G Szakács et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation
IA Manke et al.
MOLECULAR CELL (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
Microtubules as a target for anticancer drugs
MA Jordan et al.
NATURE REVIEWS CANCER (2004)
Study on surfactant coating of polymeric nanoparticles for controlled delivery of anticancer drug
L Mu et al.
COLLOID AND POLYMER SCIENCE (2004)
A novel controlled release formulation for the anticancer drug paclitaxel (Taxol®):: PLGA nanoparticles containing vitamin E TPGS
L Mu et al.
JOURNAL OF CONTROLLED RELEASE (2003)
Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1
J Sampath et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)